Clinical Trials
5
Active:1
Completed:0
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Ascorbate with Durvalumab in Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 36
- Registration Number
- NCT06083454
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 30
- Registration Number
- NCT04699838
- Locations
- 🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States
🇺🇸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
PDR001 + Panobinostat for Melanoma and NSCLC
Phase 1
Withdrawn
- Conditions
- MelanomaNon Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Muhammad Furqan
- Registration Number
- NCT03982134
Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy
Terminated
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 29
- Registration Number
- NCT03951012
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
Phase 2
Active, not recruiting
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Muhammad Furqan
- Target Recruit Count
- 32
- Registration Number
- NCT02769832
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
News
No news found